Rallybio Corporation and Avenzo Therapeutics announced a merger agreement to advance next-generation oncology therapies, alongside a $215M concurrent private placement.
Clinical-stage biotechnology company developing therapies for severe and rare diseases, with a pipeline focused on complement dysregulation and hematology
Clinical-stage biotechnology company developing therapies for severe and rare diseases, with a pipeline focused on complement dysregulation and hematology.